Free Strategic Consultancy/Review
A Quick Question or a Full Review – get in touch there is no charge
At IDA Consultants, we know that when you need the advice there is often no money to pay for it, and even when you do have a budget how do you know if a drug development consultancy really have the expertise you need. Well we have a way of working that overcomes these issues, we give all prospective clients/project an opportunity to get at our expertise without taking the risk.
We allow all projects a free strategic review / consultation via teleconfernece, with absolutley no obligation, you may come to us now for a project or in a few years time, its high quality advice and its free, what could be better.
How it works, you get in touch with a brief non-confidential description of your project, we then confirm if we can help you and organise a confidentiality agreement and organise a teleconference with our experts. Before the call you submit to us more detailed information so that we are able to really get to grips with your project, then we have the call and you can ask anything you like, we don’t just tell you we can help you we give real advice.
Obviously the advice is just that advice based on our initial assessment, whilst it might not be as comprehensive as the advice that comes from a full consultancy review, it will give you some valuable insights and enable you to assess our expertise.
So please get in touch to organise your review, 02081444960 / action@damienbove.com
Pingback: Free Strategic Consultancy - Biotechnology Pharmaceutical regulatory development | Drug Development Consultant and Regulatory Consultant
Pingback: New Draft FDA Guidance on Somatic Cell Therapy for Cardiac Disease | Drug Development Consultant and Regulatory Consultant
Pingback: Over £220 million to boost innovation in the NHS | Drug Development Consultant and Regulatory Consultant
Pingback: New EMEA Draft Concept Paper - Immunogenicity Assessment of Manoclonal Antibodies for In-vivo clinical use | Drug Development Consultant and Regulatory Consultant
Pingback: EMEA publishes a reflection paper - Recombinant Adeno-Associated Viral Vectors | Drug Development Consultant and Regulatory Consultant
Pingback: The pharmaceutical industry faces unprecedented barriers to evolution | Drug Development Consultant and Regulatory Consultant
Pingback: FDA Draft Guidance - Label Comprehension Studies for Non-prescription Drug Products | Drug Development Consultant and Regulatory Consultant
Pingback: FDA Guidance for Industry - Intergrated Summaries of Effectivenss and Safety: Location within the Common Technical Document | Drug Development Consultant and Regulatory Consultant
Pingback: FDA approves first ever Human drug from Geneticaly Engineered Animals | Drug Development Consultant and Regulatory Consultant
Pingback: US governemet to spend US$1.1 billion on Evidence Based Medicine | Drug Development Consultant and Regulatory Consultant
Pingback: Functional Foods Overstep the Claims - are Cheerios a drug the FDA think so | Drug Development Consultant and Regulatory Consultant
Pingback: EMEA puts out a new concept paper - developing a guidline for the use of Pharmcogenomic Methodologies in the Pharmacokinetic Evaluation of Medicinal Products | Drug Development Consultant and Regulatory Consultant
Pingback: FDA guidance - Submission of Bioequivalence data for ANDA's | Drug Development Consultant and Regulatory Consultant
Pingback: A Thought Provoking Consideration of Surrogate Endpoints | Drug Development Consultant and Regulatory Consultant
Pingback: EU announces 246 million Euros of medical research funding and tells us what they are looking for in the next round | Drug Development Consultant and Regulatory Consultant
Pingback: EMEA re-post Draft Guidance on the Clinical Evaluation of Anti-virals intended for HepC | Drug Development Consultant and Regulatory Consultant
Pingback: EMEA republish points to consider on clinical investigation of medicinal products used in the treatment of osteoarthritis | Drug Development Consultant and Regulatory Consultant
Pingback: EMEA re-posts Points to Consider on Missing Data | Drug Development Consultant and Regulatory Consultant
Pingback: EMEA Guidlines on Clinical Investigation of Medicinal Products for The Treatment of Ankylosing Spondylitis. | Drug Development Consultant and Regulatory Consultant
Pingback: MHRA publishes guidance on the Medical Devices Directives | Drug Development Consultant and Regulatory Consultant
Pingback: EMEA issue draft guidance on plasma-derived medicinal products | Drug Development Consultant and Regulatory Consultant
Pingback: EMEA publishes concept paper on the development of guidlines on the use of Pharmacogenomic Methodogologies in PK evaluation | Drug Development Consultant and Regulatory Consultant
Pingback: New Manchester University Spin Out Fund | Drug Development Consultant and Regulatory Consultant
Pingback: IDA consultants Provides Regulatory Roadmap | Drug Development Consultant and Regulatory Consultant
Pingback: N8, METRC, and an Associated Proof of Concept Fund | Drug Development Consultant and Regulatory Consultant
Pingback: Correction on N8 | Drug Development Consultant and Regulatory Consultant
Pingback: Technology Strategy Board - New Competitions | Drug Development Consultant and Regulatory Consultant
Pingback: FDA guidance - Q8(R1) Pharamceutical Development - submission contents and overall pharmaceutical development guidance. | Drug Development Consultant and Regulatory Consultant
Pingback: Guest Article - The Fight Against Influenza | Drug Development Consultant and Regulatory Consultant
Pingback: Guidline on Quality, Non-Clinical and Clinical Aspects of Live Recombinant Viral Vectored Vaccines | Drug Development Consultant and Regulatory Consultant